Patents by Inventor Bill Biliang ZHANG

Bill Biliang ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF
    Publication number: 20230293701
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that comprise one or more ligand moieties for an asialoglycoprotein receptor (ASGPR). Exemplary chemical entities can further comprise an oligonucleotide. Said chemical entities are useful, e.g., in the targeted delivery of oligonucleotides to liver cells (e.g., liver parenchymal cells). The chemical entities are useful e.g., in the treatment of conditions or diseases caused by the expression (e.g., abnormal expression) of one or more genes in liver cells This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: January 20, 2021
    Publication date: September 21, 2023
    Inventors: Bill Biliang ZHANG, Haoting ZHAO
  • LIPID COMPOUND AND THE COMPOSITION THEREOF
    Publication number: 20230242474
    Abstract: The invention relates to a lipid compound of formula (I), including lipid nanoparticles thereof, and the manufacturing method and the use of pharmaceutical delivery. The lipid compounds have formula (I): or a salt or an isomer thereof, wherein R1, R2, R3 n and m are defined herein.
    Type: Application
    Filed: May 27, 2021
    Publication date: August 3, 2023
    Inventors: Bill Biliang ZHANG, Haoting ZHAO, Jain WEN
  • CORONAVIRUS VACCINES AND USES THEREOF
    Publication number: 20230015616
    Abstract: This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.
    Type: Application
    Filed: November 30, 2020
    Publication date: January 19, 2023
    Inventors: Bill Biliang ZHANG, Man LI, Lin MA, Jian WEN, Hong ZHANG, Huiling ZHONG
  • Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17
    Patent number: 10709729
    Abstract: Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 14, 2020
    Assignees: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES, GUANGZHOU RIBOBIO CO., LTD.
    Inventors: Bill Biliang Zhang, Micky Daniel Tortorella, Zhe Wang, Xiuqun Yang, Qiuyun Wang
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ADAMTS-5 AND ADAM17
    Publication number: 20180250323
    Abstract: Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.
    Type: Application
    Filed: December 23, 2015
    Publication date: September 6, 2018
    Inventors: Bill Biliang ZHANG, Micky Daniel TORTORELLA, Zhe WANG, Xiuqun YANG, Qiuyun WANG